Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results
Go back to Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results| (NASDAQ: ADVM) | Delayed: 4.36 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.36 | 52 Week High | $4.86 | |||
| Open | $4.36 | 52 Week Low | $2.74 | |||
| Day High | $4.36 | P/E | N/A | |||
| Day Low | $4.36 | EPS | $0.00 | |||
| Volume | 404 | |||||
